Skip to main content
H. Lundbeck A logo

H. Lundbeck A — Investor Relations & Filings

Ticker · HLUN ISIN · DK0061804770 LEI · 5493006R4KC2OI5D3470 CO Manufacturing
Open in API
Filings indexed 947 across all filing types
Latest filing 2024-11-28 Delisting Announcement
Country DK Denmark
Listing CO HLUN

About H. Lundbeck A

https://www.lundbeck.com/global

H. Lundbeck A/S is a global biopharmaceutical company specializing in brain diseases. The company is engaged in the research, development, manufacturing, and marketing of transformative therapies for a range of psychiatric and neurological disorders. Its portfolio and pipeline focus on conditions such as depression, mood disorders, and rare childhood-onset epilepsies. Lundbeck is dedicated to advancing neuroscience to improve the quality of life for individuals affected by central nervous system disorders.

Recent filings

Filing Released Lang Actions
Delisting Announcement 2024
Delisting Announcement Classification · 99% confidence The document is explicitly titled "CORPORATE RELEASE" and announces the successful completion and expiration of a tender offer by Lundbeck to acquire Longboard Pharmaceuticals. It details the transaction value, closing date, and the subsequent delisting of Longboard's stock. This type of announcement, detailing a major corporate action like an acquisition/takeover, fits the definition of M&A Activity (TAR). While it mentions SEC filings (Schedule TO, Schedule 14D-9), the primary purpose of this specific document is to communicate the outcome of the takeover bid, not to be the primary regulatory filing itself. Therefore, TAR is the most appropriate classification.
2024-11-28 English
Regulatory Filings 2024
Regulatory Filings Classification · 99% confidence The document is a press release from H. Lundbeck A/S announcing positive results from a Phase III pivotal clinical trial (*SUNRISE*) for their drug Vyepti® in migraine prevention. It details efficacy endpoints, safety profiles, and future regulatory plans in Asia. This type of announcement, focusing on clinical trial outcomes and immediate business implications, is characteristic of an Earnings Release (ER) or a general announcement related to product development/results. Since it is a specific announcement of results rather than a comprehensive periodic report (like 10-K or IR), and it is not a transcript (CT) or a formal presentation (IP), the most fitting category is Earnings Release (ER), as these often include key clinical trial updates when they coincide with reporting periods or are material news. Given the content is a major positive clinical update, it functions as a key piece of news for investors, aligning best with ER, although it could also be considered RNS if it were purely regulatory. However, the detailed results presentation strongly suggests an ER context.
2024-10-31 English
Lundbeck announces positive results from phase III pivotal trial (SUNRISE) of Vyepti® (eptinezumab) in migraine prevention
Regulatory Filings Classification · 95% confidence The document is a corporate release from H. Lundbeck A/S announcing positive phase III clinical trial results for their drug Vyepti. It details the trial methodology, efficacy endpoints, and future regulatory plans. This type of announcement regarding clinical trial outcomes is standard for pharmaceutical companies and falls under the category of general regulatory announcements or corporate releases, which are classified as RNS in this schema.
2024-10-31 English
M&A Activity 2024
M&A Activity Classification · 99% confidence The document is a corporate release dated October 14, 2024, announcing that H. Lundbeck A/S will acquire Longboard Pharmaceuticals via a tender offer for approximately USD 2.6 billion. This announcement details a merger/acquisition transaction, including the proposed price, financing, and expected closing timeline. This clearly falls under the category of M&A Activity (TAR). It is not a standard financial report (10-K, IR, ER) nor a general regulatory filing (RNS), but a specific announcement about a takeover proposal.
2024-10-14 English
Lundbeck to acquire Longboard Pharmaceuticals in a strategic deal, significantly enhancing its neuroscience pipeline
M&A Activity Classification · 100% confidence The document is a formal press release announcing a definitive agreement for Lundbeck to acquire Longboard Pharmaceuticals. It details the strategic rationale, transaction value, terms of the tender offer, and future integration plans. Since this is a specific announcement regarding a merger and acquisition (M&A) transaction, it falls under the 'M&A Activity' category.
2024-10-14 Danish
Earnings Release 2024
Earnings Release Classification · 100% confidence The document provides key financial highlights for the first six months of 2024 (H1 2024), including revenue, adjusted EBITDA, and EPS comparisons to H1 2023. It details performance metrics for strategic brands, discusses recent corporate/pipeline events (collaboration modification with Takeda, FDA submission updates), and explicitly states that the 'Financial guidance 2024 raised'. This structure—summarizing period performance, providing key figures, and updating guidance—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it focuses heavily on the 'Key highlights' and 'Key figures' for the first half of the year, it aligns best with an Interim/Quarterly Report (IR), which is a comprehensive report for a period shorter than a year. Although it contains elements of an Earnings Release (ER) by announcing guidance raised, the depth of the financial tables and narrative suggests a more comprehensive interim report than just the initial press release highlights. H1 2024
2024-08-20 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.